Compare Adaptive Biotechnologies Corp (ADPT) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Vanguard S&P 500 ETF — how do they compare? Adaptive Biotechnologies Corp trades at $25.01 (market cap $4.04B), while Vanguard S&P 500 ETF trades at $709.73. Which is the better fit depends on your goals.
| ADPT | VOO | |
|---|---|---|
Market Cap | $4.04B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $25.45 | $710.71 |
52-Week Low | $12.30 | $580.93 |
Enterprise Value | $4.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
VOO trades at $710.44, down slightly by 0.02% today, with a bullish technical signal from moving averages but overbought RSI readings. The ETF is near record highs amid strong S&P 500 performance, supported by AI-driven earnings growth and institutional inflows. Recent dividend activity includes a $1.96 distribution scheduled for June 2026.
Outlook remains positive due to robust corporate earnings and upward analyst targets, but risks include high valuations and potential market pullbacks. Investors benefit from broad market exposure, though caution is warranted given elevated sentiment and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
